Zydus Lifesciences Gears Up For Expansion Into Medtech Through Amplitude — Motilal Oswal Maintains Neutral

NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Motilal Oswal Report

Zydus Lifesciences Ltd. has entered into exclusive negotiations to acquire Amplitude Surgical, extending its scope of business in the medtech segment.

Amplitude delivered 5% YoY growth in sales for six months ending in Dec’24, with Ebitda margin of 25.4%. The acquisition would be at four times enterprise value/12 months sales and 15.7x EV/12 months Ebitda.

The acquisition is a part of Zydus’ priority verticals in the medtech segment to build its global presence.

Zydus is enhancing its existing growth levers such as-

1. differentiated product pipeline/manufacturing for US generics,

2. day-1 launches/next generation drug delivery platforms for India market, and

3. niche product pipeline in biosimilar, vaccine and NCE segments.

Zydus is further adding growth levers in its medtech segment (cardiology, nephrology, orthopaedics). However, considering stable earnings over FY25-27, we maintain Neutral rating on the stock.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.